Background & Aims: Current models of colorectal adenoma to carcinoma progression do not
Introduction
Colorectal adenomas are highly prevalent lesions occurring in more than 30% of the normal population over age 60 years [1] . However, only about 5% of these adenomas ever progress to cancer. The ability to distinguish adenomas that do progress to cancer from those that will not progress is highly relevant for colorectal cancer screening. Because this difference cannot be reliably made macroscopically, endoscopic screening strategies aiming to detect and remove all adenomas will be inherently unspecifi c -most of the adenomas removed would not have progressed to cancer anyway. Because colorectal tumor progression is driven by an accumulation of genetic abnormalities, genetic testing focused specifi cally at these genetic alterations may show a higher specifi city for discriminating adenomas with a high risk of progression from adenomas that will not progress [2] . Theoretically, achieving this goal would require a prospective study design in which DNA is sampled from colorectal adenomas, which are subsequently left in situ for 10-15 years to see whether or not they progress to cancer. However, this is not feasible. Instead, crosssectional studies must be used to obtain this information.
Therefore, in this article we present a cross-sectional study of a total of 194 colorectal tumor samples, comparing genetic data from colorectal adenomas that had demonstrated a capacity for progression to carcinoma (because they already contained a focus of carcinoma) to a random set of nonprogressed adenomas without evidence of cancer at the time of resection. Because in general, only 5% of colorectal adenomas will ever progress to cancer, this can be regarded as a reliable set of controls. In addition, a set of colorectal carcinomas was included. Chromosomal aberrations were analyzed on a genomewide scale, using comparative genomic hybridization, supplemented by mutation analysis of APC and KRAS. Data analysis focused on cancer-associated genetic changes in adenomas. Using hierarchic cluster analysis, we set out to defi ne subsets of tumors with distinct patterns of these cancer-associated chromosomal aberrations.
Concerning the molecular pathways underlying tumor progression, we know that genetic changes lead to the disruption of critical biologic functions and that they arise as a consequence of genomic instability, which in sporadic colorectal cancer occurs mainly at the chromosomal level [3] . Our current understanding of colorectal tumorigenesis has been based on the analysis of a relatively limited number of genetic changes [4] [5] [6] , and thus has resulted in models suggesting a linear sequence of events leading to cancer. In the model presented by Vogelstein et al. [7] , KRAS mutation and loss of heterozygosity on chromosome 5q (the APC tumor-suppressor gene locus) are early genetic changes, whereas loss of heterozygosity of 18q (initially DCC, but later Smad4) and 17p (p53) were considered late events.
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Although this model has been revolutionary in our understanding of the multistep pathogenesis of human sporadic colorectal cancer, it now appears that it cannot fully explain the heterogeneity and complexity of colorectal cancer. Several frequent chromosomal aberrations are not taken into account, including losses of 8p and 15q and especially gains of 8q, 13q, and 20q, as has been revealed by genome-wide chromosomal analysis using comparative genomic hybridization (CGH) [8] [9] [10] [11] .
How all of these events would fi t into a linear model of tumor progression is not immediately clear. Only the study of large numbers of cases based on the analysis of many genetic parameters simultaneously will allow the unravelling of the complex relationships between these events, enabling more exact modeling.
Material and Methods

Tumor material
A total of 194 tumor samples were studied, consisting of 66 nonprogressed adenomas (i.e., simple adenomas without invasion), 46 progressed adenomas (in which a focus of carcinoma already is present, also referred to as malignant polyps), of which both the adenoma part and the carcinoma part were analyzed separately; and 36 simple carcinomas. The samples were obtained from 93 patients, 41 female and 52 male. The mean age was 67 years (range, 40-91). Thirty patients had multiple tumors: 5 had multiple adenomas, and 25 had 1 or more adenomas next to a carcinoma.
Histopathologic characteristics are listed in Table 1 .
Analysis of grade of dysplasia and histologic type of adenoma, as well as differentiation grade and stage of carcinoma, was performed by 1 observer (G. M.) on hematoxylin and eosin-stained sections. For each tumor tissue sample, DNA was extracted from 15 10-μm paraffi n sections, dissecting the most tumor-rich areas, allowing a maximum of 20% nontumor cell contamination [12] . Special care was taken to obtain highquality DNA from the formaldehyde-fi xed, paraffi nembedded tissues. DNA extracted from archival material can be partly degraded and cross-linked, the extent of which depends on the pH of the formaldehyde and the time of the fi xation before paraffi n embedding. To improve the quality of the isolated DNA, we have developed a very elaborate DNA extraction protocol especially for paraffi n tissues, based on the protocol published by Isola et al. [13] . It includes thorough deparaffi nation with xylene, methanol washings to remove all traces of the xylene, and a 24-hour incubation in 1 mol/L sodium thiocyanate to reduce cross-links.
Subsequently, the tissue pellet is dried and digested for 3 days in lysis buffer (155 mmol NH4Cl, 10 mmol KHCO3, 0.1 mmol Na2EDTA, pH 7.4) with high doses of proteinase K (fi nal concentration 2 μg/μL, freshly added twice a day). Finally, the DNA is purifi ed with Qiagen columns. With this Chromosomal instability in adenoma to carcinoma progression | 43 protocol, described in detail by Weiss et al. [14] , generally around 90% of all formaldehyde-fi xed, paraffi n-embedded tissue samples yield DNA of good quality and lengths between 2000 and 20,000
bp. The present study included only cases that yielded good-quality DNA The DNA was used for CGH analysis and mutation analysis of KRAS and APC. CGH was completed in all cases, but for the other tests it was not possible to perform all analyses on all tumor samples.
Therefore, the number of cases analyzed is shown between brackets for each analysis.
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Comparative Genomic Hybridization CGH (n=194) was performed as previously described [14] . Normal metaphase spreads were obtained by culturing lymphocytes from a healthy female donor, according to standard procedures. The sequencing reactions for the biotinylated products of the inside PCR were carried out using an autoload solid-phase sequencing kit (Amersham Biosciences Europe GmbH, Roosendaal, The Netherlands) with extended Cy5-labeled primers according to the manufacturer's instructions.
Briefl y, the PCR product is captured on a sequencing comb coated with streptavidin. After removal of the nonbiotinylated strands by alkaline denaturation, the remaining immobilized strand is used as a template for dideoxy sequencing reactions with a Cy5-labeled primer and T7 DNA polymerase.
In this system, only full-length immobilized PCR product is available for sequencing. The purifi ed 
KRAS mutation analysis
KRAS mutation analysis (n=78) was done by PCR using an oligonucleotide 20-mer panel of codons 12 and 13 (TIB Molbiol; Advanced Biotechnology Center, Genova, Italy) as previously described [16] . Extracted DNA from peripheral blood lymphocytes from healthy donors was used as wildtype KRAS codon 12 GGT-gly and codon 13 GGC-gly controls, and extracted DNA from 6 different colon cancer cell lines was used as control for known KRAS mutations.
Statistical analyses
The and Treeview software (http://rana.lbl.gov/EisenSoftware.htm) were used with the settings "complete linkage" and "uncentered correlation" as a similarity metric. No "self-organizing map" preclustering was performed. For the hierarchic cluster analysis, chromosomal gains were coded as 1 and chromosomal losses were coded as -1. To avoid overinterpretation of the data, only fi rstand second-generation clusters (i.e., the fi rst-and second-level branches of the tree) were used for classifi cation purposes.
Results
Comparative Genomic Hybridization results in relation to adenomacarcinoma progression
Nineteen nonprogressed adenomas did not show any chromosomal abnormality. The remaining 47 nonprogressed adenoma cases showed few chromosomal aberrations (on average, 4.6). These aberrations showed a rather random distribution over the chromosomes, although there were Chromosomal instability in adenoma to carcinoma progression | 47 more losses than gains (ratio of loss to gain, 2:7). The average number of chromosomal aberrations in the 46 progressed adenomas was 10.5, signifi cantly higher than in the nonprogressed adenomas (P=0.000) and similar to the value found in the carcinomas. Here losses and gains were more equally distributed (ratio of loss to gain, 1:3). Six chromosomal abnormalities occurred in more than 35% of cases: loss at 8p21-pter, 15q11-q21, 17p12-13, and 18q12-21 and gain at 8q23-qter and 13q14-31 (Table 2 ).
In all but 1 of 46 carcinoma parts of malignant polyps, and in all simple carcinomas, many chromosomal abnormalities were observed (average, 11.4 and 10.5, respectively). Seven chromosome changes occurred in more than 40% of cases. These were losses at 8p21-pter, 15q11-q21, 17p12-13, and 18q12-21 and gains at 8q23-qter, 13q14-31, and 20q13 (see Table 2 ). Because these events were associated with both the carcinomas and the adenomas that had already progressed to adenomas, they are further referred to as cancer-associated events. The distribution of these cancerassociated events over the different categories of lesions is depicted in Figure 1 . 
APC and KRAS in relation to adenoma-carcinoma progression
No signifi cant differences in APC mutations were found between the groups; frequencies ranged from 54% in the simple adenomas to 71% in the carcinomas ( Table 2 
Genetic data in relation to histopathologic characteristics
In the 112 adenomas, the number of CGH abnormalities was signifi cantly correlated with grade of dysplasia (P=0.002), but not with histologic type or size ( Table 2 ). The same was found for the number of cancer-associated events (P=0.000). Nevertheless, after stratifi cation for grade of dysplasia, a signifi cant difference in number of cancer-associated events between progressed and nonprogressed adenomas persisted (Figure 2 ). In addition, 2 specifi c chromosome changes -loss of 18q and gain of 20q -correlated with grade of dysplasia (P=0.000 for both). Table 2 ).
Comparative Genomic Hybridization results: hierarchic cluster analysis
Hierarchic cluster analysis of CGH results was performed in the 112 adenomas (i.e., 66 nonprogressed adenomas and 46 adenoma parts of malignant polyps), for ordering correlated groups of both tumors and chromosomal aberrations. This resulted in 4 clusters of colorectal adenomas (based on the fi rst-and second-level branches of the tree), with distinctive patterns of chromosome changes ( Figure 3A ; Table 3 ). Adenomas in cluster 1 (AC1) showed no abnormalities.
Adenomas in cluster 2 (AC2) had few abnormalities, consisting predominantly of losses, with loss of 17p and 20q as well as KRAS mutation (>40% for all 3) as main characteristics. In contrast, AC3
and AC4 showed a high number of both losses and gains. AC3 contained more than 40% gains of 2q, 5q, 6q, 7p+q, 8q, and 13q and loss of 17p, whereas AC4 showed more than 40% losses of 5q and 18q and gains of 12q and 20p+q. Certain associations between histologic type and the clustering results were observed (Table 3) , whereas other parameters, including APC mutation and grade of dysplasia, did not differ between the clusters.
Hierarchic cluster analysis of the 82 carcinomas (i.e., both carcinoma parts of 46 malignant polyps as well as 36 simple carcinomas) yielded 2 fi rst-and second-generation carcinoma clusters for further evaluation. (One fi rst-generation cluster, containing only a single carcinoma without any chromosomal abnormalities, was excluded from further analysis.) These 2 clusters (CC1 and CC2)
showed a similar distribution of carcinoma parts of malignant polyps and simple carcinomas, and no differences in degree of differentiation or Astler-Coller stage ( Figure 3B and Table 3 ). CC1 had >40% losses of 11q, 12q, 17p, 17q, 18q, and 21q, whereas CC2 had >40% gains of 7p+q and 20q and loss of 18q. Gains of 8q and 13q occurred in more than 40% of both clusters. The chromosome abnormalities found in AC2 and AC4 matched with those found in CC1 and CC2, respectively, whereas AC3 appeared to be an intermediate group. This similarity was confi rmed in an independent hierarchic cluster analysis run in which all 194 adenoma and carcinoma cases were entered together (Table 4 ). Tumors are grouped on the basis of similarities in chromosomal aberrations following the tree displayed on top. Some chromosomal abnormalities are closely correlated, such as 8q and 13q gains, both in the (A) adenomas and in the (B) carcinomas. Only fi rst-and secondgeneration tumor clusters (the fi rst-and secondlevel branches of the tree) were used for classifi cation purposes. In the adenoma tree, 4 clusters emerged, whereas in the carcinoma tree, 2 major clusters appeared (next to 1 carcinoma that did not show any chromosomal abnormality). NOTE. Vertical axis: clustering of 112 adenomas and of 82 carcinomas seperately versus horizontal axis: clustering of all 194 tumors together. The separate clustering yielded 4 adenoma clusters and 2 carcinoma clusters; the latter resulted in three clusters; the clustering of all tumor cases together resulted in 3 all tumor clusters. The all tumors cluster 1 cases showed no chromosomal aberrations and completely matched with adenoma cluster 1. All cases in adenoma cluster 2 and carcinoma cluster 1 completely were assigned to all tumors cluster 2, whereas 80% (47 out of 59) of adenoma cluster 4 and carcinoma cluster 2 cosegregated with all tumors cluster 3. Cases from adenoma cluster 3 distributed all over cluster 2 (72%) and all tumors cluster 3 (28%).
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Discussion
Current genetic models of colorectal adenomacarcinoma progression do not refl ect the complexity of the disease. We compared genomewide chromosomal aberrations in nonprogressed adenomas to adenomas proven capable of progression toward malignancy. The present data, obtained from a cross-sectional study of a total of 194 tumor samples, revealed that gains at 8q23-qter, 13q14-31, and 20q13 and losses at 8p21-pter, 15q11-q21, 17p12-13, and 18q12-21 were strongly associated with advanced lesions, including both adenomas that contained foci of carcinoma and simple carcinomas. These former lesions implicitly demonstrated their capability of progression. The presence of these "cancer-associated events" in colorectal adenoma thus could be an indicator of high risk of progression. In addition, the present study yielded evidence for the association of multiple independent patterns of chromosomal aberrations associated with progressed adenomas and colorectal carcinomas, suggesting the presence of multiple chromosomal instability pathways toward colorectal cancer.
The accumulation of cancer-associated events correlated with progression from simple adenoma to adenomas with foci of cancer (malignant polyps). Surprisingly, after stratifying for dysplasia, progressed adenomas (i.e., adenomas containing a focus of carcinoma) had a signifi cantly higher number of cancer-associated events than did nonprogressed adenomas with the same grade of dysplasia (Figure 2 ), indicating that in this respect genetic characteristics are more informative than morphologic characteristics.
The presence of cancer-associated events turned out to be a relatively strong indicator of progression toward malignancy in colorectal adenomas. Because screening strategies should detect adenomas that are actually likely to progress rather than the highly prevalent, indolent type of adenomas that do not progress, the reported cancer-associated events could become clinically important. The mean number of cancer-associated events appears to be a good discriminator between progressed and nonprogressed lesions. Putting the data in a receiver operator characteristic (ROC) curve, an area under the curve of 87% emerged, and when using the presence of 2 cancer-associated events as cutoff, a 78% sensitivity with a 78% specifi city was achieved ( Figure 1B ). This is comparable to, or even better than, for example, the performance of fecal occult blood testing [17] . Figure 1 shows that indeed the vast majority of lesions with 2 or more cancer-associated events were progressed lesions. However, only a minority of progressed lesions had 4 or more cancer-associated events, which may indicate that it is not the mere accumulation that is important in carcinogenesis, but rather the acquisition of some specifi c combinations of events.
Indeed, hierarchic cluster analysis revealed the presence of specifi c combinations of alterations.
Of the 7 cancer-associated events, 5 segregated over 3 distinct adenoma clusters (Table 3 ). The of genetic abnormalities, are essential for progression [18] . Interestingly, a separate clustering of the 82 carcinomas resulted in 2 clusters that showed great similarity with 2 of the adenoma clusters.
This was confi rmed when all adenomas and carcinomas were clustered together (Table 4) . These data are compatible with the existence of multiple routes of progression through chromosomal instability ( Figure 4 ).
These data show that chromosomal instability does not cause merely random genetic noise, but instead distinct, statistically highly signifi cant patterns of associated chromosomal changes. In the end, the functional consequences of these chromosomal aberrations on gene expression level are what cause tumor progression. As a consequence, the respective chromosomal regions are likely to harbor gatekeeper genes involved in different cell biologic processes, such as proliferation, apoptosis, invasion, remodeling of extracellular matrix, stroma induction, and escape from the immune system [19] . Comparison of microsatellite-instable and chromosomal-instable colorectal cancers supports the concept of specifi c molecular pathways being disrupted in different ways.
Although in microsatellite-instable colorectal cancers the balance of proliferation and differentiation is altered by TGFbRII mutation [20] and apoptosis is altered by BAX mutation [21] , in chromosomalinstable colorectal cancers, the same pathways can be impaired via 18q loss (Smad4) and 17p loss (p53) [20] [21] .
The present data indicate that even within the group of chromosomal-instable colorectal tumors, different ways may exist to affect the same cellular functions. The most obvious candidate genes that are compatible with the chromosomal changes found are p53 on 17p12 and Smad4 on 18q21.
For the other cancer-associated events, this remains to be determined. Further studies are needed to elucidate which critical molecular pathways are affected by these chromosomal alterations, and how these contribute to colorectal adenoma-carcinoma progression.
Our data are consistent with the recent fi nding that a certain degree of genomic instability is already present in very small (i.e., early) adenomas [22] [23] [24] . In small, nonprogressed adenomas, chromosomal aberrations were sometimes found, mostly losses. Disruption of the Wnt pathway, frequently by loss of APC function, is the earliest factor causing the development of colorectal adenomas [25] , and in mouse models APC mutation has been found to be associated with Chromosomal instability in adenoma to carcinoma progression | 57 chromosomal instability [26, 27] . However, because APC mutations occur in the vast majority of adenomas (including microsatellite-instable adenomas that have normal karyotypes [28] , and because only about 5% of these adenomas ever progress to cancer, it is unlikely that loss of APC function is the sole determining factor in chromosomal instability in colorectal adenomas. Indeed, in our study, the increase of chromosomal aberrations found to be associated with adenomacarcinoma progression was not correlated with the presence of APC mutations. Therefore, other factors must be involved in accelerating genomic instability [29] .
We conclude that the acquisition of 2 or more cancerassociated events is associated with progressed colorectal adenomas and carcinomas. In addition, this association involves specifi c combinations of a few chromosomal abnormalities, rather than the mere accumulation of events.
Evidence is shown for the existance of multiple chromosomal instability pathways of colorectal cancer progression, each of which may possibly disrupt similar cell biologic functions, such as proliferation, differentiation, apoptosis, and invasion, in different manners.
